Navigation Links
DURECT Announces ELADUR® (TRANSDUR®-Bupivacaine) Phase II Study Results in Chronic Low Back Pain
Date:4/11/2011

CUPERTINO, Calif., April 11, 2011 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today top-line results from a Phase II clinical trial in chronic low back pain for ELADUR® (TRANSDUR®-Bupivacaine), DURECT's proprietary investigational transdermal bupivacaine pain patch.  This study was conducted by DURECT's collaborator, King Pharmaceuticals, which is now owned by Pfizer (NYSE: PFE).  In this study of 263 patients suffering from chronic low back pain, the primary efficacy endpoint of demonstrating a positive treatment difference for the mean change in pain intensity scores from baseline to the mean of weeks 11 and 12 between ELADUR as compared to placebo was not met.  Complete data analysis is on-going.

(Logo:  http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

ELADUR is an investigational transdermal drug patch intended to deliver bupivacaine for up to 3 days from a single application.  Bupivacaine, the active agent in ELADUR, is a potent, FDA-approved long-acting local anesthetic used in regional anesthesia for local tissue infiltration, nerve block, and epidural and intrathecal anesthesia.  ELADUR demonstrated a positive efficacy trend in a Phase 2a study for post-herpetic neuralgia (PHN); a poster describing this study was presented at the 27th Annual Scientific Meeting of the American Pain Society on May 8, 2008 and is accessible on DURECT's website (http://www.durect.com/wt/durect/page_name/Publications).

"Demonstrating efficacy against placebo in a chronic low back pain trial is challenging for any topical locally-acting product," stated James E. Brown, DVM, President and CEO of DURECT.  "We and Pfizer are continuing to analyze this most recent study and will work
'/>"/>

SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. DURECT to Present at Cowen and Company Health Care Conference
2. DURECT Corporation Invites You to Join its Fourth Quarter 2010 Earnings Conference Call
3. DURECT Reports Data From European Phase IIb Shoulder Study of POSIDUR™ (SABER™-Bupivacaine) and Amendment of the Nycomed Agreement
4. DURECT Announces Launch of First FDA Approved SABER™-Injectable Peptide Product
5. DURECT to Present at the BIO CEO & Investor Conference
6. DURECT to Present at the Credit Suisse 2010 Healthcare Conference
7. DURECT Corporation Announces Third Quarter 2010 Financial Results
8. DURECT Corporation Invites You to Join Its Second Quarter 2010 Earnings Conference Call
9. DURECT to Present at the BMO Capital Markets Focus on Healthcare Conference
10. DURECT Corporation Secures $50 Million Committed Equity Financing Facility
11. DURECT Reports Data From European Phase IIb Hysterectomy Study of POSIDUR(TM) (SABER(TM)-Bupivacaine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014  KIYATEC announced today that it ... Innovation Research (SBIR) Phase II Contract from the ... institutes and centers that comprise the National Institutes ... two year award, KIYATEC will expand its 3D ... the forefront of cancer therapy strategies: 1) cancer,s ...
(Date:9/18/2014)... PLYMOUTH MEETING, Pa. , Sept. 18, ... eClinical trial solutions, was recognized as the ... 2014 for its ePharmaONE cloud-based eClinical platform. ... portal and electronic trial master file (eTMF), ... informed-consent solution, and ePharmaSolutions, ReferralPlus+ patient screening ...
(Date:9/18/2014)... , Sept. 18, 2014   3D Systems   (NYSE: ... Simbionix RobotiX Mentor™ , a new robotic surgery skills ... first time at the ERUS exhibition in Amsterdam, ... #7). Robotic-assisted minimally invasive surgery represents a growing ... the needs for training for robotic surgery has increased, and ...
Breaking Medicine Technology:National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 3ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 2ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 33D Systems Introduces New Simbionix Robotics Training Platform 23D Systems Introduces New Simbionix Robotics Training Platform 3
... BOSTON, Jan. 27, 2011 Solos Endoscopy, Inc. (OTCPK: SNDY) ... the three months ended December 31, 2010 in the amount ... a result of instrument sales to over fifty Hospitals, Clinics, ... States. Solos looks towards continued growth in 2011 ...
... /PRNewswire-Asia/ -- Weikang Bio-Technology Group Co., Inc. ... the "Company"), a leading developer, manufacturer and marketer of ... and other health and nutritional products in the People,s ... products, Ranitidine Hydrochloride Capsule, has been added to the ...
Cached Medicine Technology:Solos Endoscopy, Inc. Reports $90,005 in Sales Revenue for Fourth Quarter 2010 2Weikang Bio-Technology Announces Inclusion of Ranitidine Hydrochloride Capsule on National Drug Reimbursement List 2Weikang Bio-Technology Announces Inclusion of Ranitidine Hydrochloride Capsule on National Drug Reimbursement List 3
(Date:9/18/2014)... 2014 Memorial Cardiac and Vascular ... week by performing the first ever, adult heart transplant ... for Organ Sharing) approval to launch the adult heart ... two programs in South Florida. , The skilled ... Gongora, Medical Director of the Adult Heart Transplant ...
(Date:9/18/2014)... September 19, 2014 A jacket is ... A jacket typically has sleeves, and fastens in the ... generally lighter, tighter-fitting, and less insulating than a coat, ... serve as protective clothing. Today, Fecbek, a well-known clothing ... of trendy men’s jackets; all these items are offered ...
(Date:9/18/2014)... Sept. 18, 2014 (HealthDay News) -- Rising temperatures in ... to spread to shallow waters that are becoming warmer, ... coral reefs, ecologists report. A study of 40 ... shows northward movement by the invasive and poisonous lionfish, ... Administration (NOAA) and the University of North Carolina-Wilmington, who ...
(Date:9/18/2014)... Steven Reinberg HealthDay Reporter ... sign that the Ebola outbreak in West Africa is starting to ... more than 700 new cases of the deadly viral infection were ... of cases to more than 5,300, with roughly half of those ... reported. The number of deaths now tops 2,600. WHO has ...
(Date:9/18/2014)... 18, 2014 Limited spots remain at ... Only 100 spots are still available for Becker's ASC ... ASCs on October 23-25, 2014 at the Swissotel Chicago. ... Chief Information Officer Strategy Roundtable on November 4, 2014 ... remain for Becker's Hospital Review Chief Executive Officer Strategy ...
Breaking Medicine News(10 mins):Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 2Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 3Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 4Health News:Cool Jackets Are For Sale At Fecbek.com 2Health News:Rising Atlantic Ocean Temperatures Could Pose Threat to Reefs 2Health News:New Ebola Cases Top 700 in Just One Week, Officials Report 2Health News:New Ebola Cases Top 700 in Just One Week, Officials Report 3Health News:Limited Spots Remain at Becker's Upcoming ASC and Hospital Conferences 2
... for Complimentary Services and Fund Raising Program In ... 15 Westside Medical Spa today,announced the launch of "Face ... preparing to embark on a new chapter in their lives.,Structured ... the,Day" has partnered with Jenesse Center Inc., in support of ...
... - Aspreva Pharmaceuticals,Corporation (NASDAQ: ASPV ; TSX: ... of evidence-based medicines available for patients,living with less ... financial and business results for the third quarter ... Aspreva will host a conference call to discuss ...
... for Unwanted Babies, Prevents Abandonment, HARRISBURG, Pa., Oct. ... today reminded expectant,parents and parents of newborns that Pennsylvania,s ... infants, up to 28 days old, to,any hospital as ... Sharon, Mercer County, a newborn girl was found in ...
... issue of the Journal of General Internal Medicine, geriatrics researchers ... Center for Aging Research and the Regenstrief Institute, Inc. say ... adults, cannot meet the needs of the growing number of ... system approaches dementia. , We have a ...
... Comment on Role of Screening,Colonoscopy in Reducing ... Today,s news from the,CDC and American ... cancer,deaths in the United States includes heartening ... of the nation,s leading gastrointestinal,specialists are convening ...
... Obligations to Laurus Fully Repaid, LARGO, Fla., ... Board: DYHP.OB) ("Dynamic"), a leading distributor in,the sports ... it filed its Articles of Merger with the ... Nasdaq of its merger with GeoPharma, Inc.,(Nasdaq: ...
Cached Medicine News:Health News:Westside Medical Spa Launches 'Face the Day' to Aid Battered Women 2Health News:Aspreva to Announce 2007 Third Quarter Results on October 31st 2Health News:PA Department of Public Welfare Reminds New Parents About 'Safe Haven' Law 2Health News:Editorial says primary care system must change how it approaches dementia 2Health News:Dynamic Files Articles of Merger; Notifies Nasdaq of Merger with GeoPharma 2Health News:Dynamic Files Articles of Merger; Notifies Nasdaq of Merger with GeoPharma 3
... its wide orifice tip, the Finntip Wide ... suspensions and macromolecules like genomic DNA. This ... cell fragmentation. It is excellent for use ... model, the inside diameter of the orifice ...
... have been designed to optimize the accuracy ... our tip products is widely recognized by ... has been extended over the years and ... and special tips including filter tips, certified ...
MBP's equivalent to the "Universal Yellow" tip, this 200 L tip utilizes a MicroPoint design for accurate sample handling. 10 L Ref. mark....
The LH ELISA kit is used for the quantitative measurement of LH in human serum or plasma....
Medicine Products: